Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Core Insights - Adaptive Biotechnologies has entered into two non-exclusive agreements with Pfizer to utilize its T-cell receptor (TCR) discovery capabilities and immune receptor antigen mapping data for research in rheumatoid arthritis (RA) [1][3][5] Group 1: Agreements Overview - The first agreement focuses on identifying disease-causing TCRs in RA, where Adaptive will analyze Pfizer's clinical samples to find common TCRs enriched in RA patients [3] - The second agreement involves licensing Adaptive's TCR-antigen datasets, which are claimed to be the largest and highest quality available, for use in developing AI and machine learning models at Pfizer [4][6] Group 2: Financial Aspects - Adaptive will receive an upfront payment from Pfizer and may be eligible for additional payments that could total up to approximately $890 million, contingent on data delivery, development, and commercialization milestones [5] - Specific financial terms of the TCR-antigen data licensing agreement have not been disclosed, but it is a multi-year, non-exclusive agreement [6] Group 3: Company Background - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment, with a goal to develop immune-driven clinical products tailored to individual patients [7]